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We still believe that economic aspects are es-
sential to build a well-functioning health care 
system, in order to develop governance poli-
cies that ensure equitable access to essential 
medical products, vaccines and technologies, 
and people’s access to needed services.
Nonetheless, we perceive the inherent limi-
tations of the predominantly utilitarian ap-
proach and the necessity to overcome the 
limitations of the standard CEA and CUA 
analyses. Prioritizing the appropriateness 
analysis for each patient is the final goal to 
optimize not only health care outcomes, but 
also the economic balance of health care sys-
tems.
In this new scenario, we felt the need to re-
think our journal. Starting from this issue 
of Farmeconomia – Health economics and 
therapeutic pathways, our intention will be to 
wide the journal contents, publishing articles 
that reflect current discussions and priorities 
in health economics. To this purpose, we en-
larged the scientific board, involving many 
experts among different countries across the 
world. The scientific board reflects the idea 
of authors and readers we’d like to reach: cli-
nicians and researchers in various countries 
who wish to exchange national and interna-
tional experiences and research results about 
the economic factors that affect the evolution 
of their health care systems. The final aim of 
our journal will be to provide an overview of 
the Italian health care system to non-Italian 
readers, while spreading in Italy the experi-
ences of other countries and settings.
This new approach to re-defining the 
Farmeconomia mission has allowed us to 
capitalize on one of our key underlying val-
ues: open access. By access to its articles by 
all readers, the journal aims at spreading the 
knowledge about economics topics, incentiv-
ising the debate among readers.
No doubt it is a big challenge. However, it 
is certainly worthy to compare different situ-
ations, increasing the dialogue in academic 
and scientific community.
We hope such changes and innovations will 
stimulate renewed interest to a wider reader-
ship of researchers, stakeholders and deci-
sion makers.
Almost 11 years ago, Farmeconomia e per-
corsi terapeutici was launched as the first 
Italian journal about pharmacoeconomics. 
When it was launched, the journal aimed at 
being a reference in this field in the Italian 
setting where concepts and terminology of 
economic evaluations were quite new.
Over the past decade, many things have 
changed.
The health care systems, created during a 
period of relative prosperity in the developed 
world, are now facing the effects of the glob-
al financial slowdown. Economic aspects are 
becoming even more important. Across Eu-
rope, public expenditure is always increas-
ing, and new methods to balance budgets and 
restrain spending are needed. Reflections on 
ways to generate new resources, inspired by 
equity and efficiency principles, are essential 
for all the stakeholders.
The business climate for pharmaceutical 
companies has consistently changed as well, 
both in structure and strategies. We assisted on 
the one hand to the merging of many compa-
nies in few Big Pharma, and on the other hand 
to the launch of highly-innovative start-ups.
The companies are facing the breaking out of 
the blockbuster mentality and the challenges 
related to the generication of their block-
buster products. Nonetheless, developing 
new medicines is more important than ever 
before, and investments in new technologies 
offer new ways to improve the medicines 
development process and foster innovation. 
R&D strategies of new drugs are increasing-
ly oriented towards individualized therapies, 
use of biomarkers, niche indications and or-
phan diseases. Finally, the rising cost of new 
drugs represents a threat to the financial sus-
tainability of the welfare and health care sys-
tem even of the richest countries.
Also pharmacoeconomics has grown and 
changed rapidly in recent years, with a wider 
use of analyses based on controlled clini-
cal trials and observational studies, the use 
of advanced techniques of modelling and 
simulation (DES-Discrete Event Simulation, 
MABS-Multi Agent Based Simulation), and 
the integration of CEA, CUA and BIM tech-
niques with HTA processes.
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